Wanbury Reports Growth and Strategic Expansion in Q2

Standalone Revenue for the quarter reached Rs 182.91 crore, with a Net Profit of Rs 11.88 crore.

Reader Takeaway: Strong sequential profit growth paired with entry into high-growth dermatology and baby care markets provides a new revenue pillar.

What just happened

Wanbury Ltd has released its financial results for the quarter ending September 30, 2026. The standalone revenue from operations climbed to Rs 182.91 crore from Rs 165.58 crore in the previous quarter. The company also introduced consolidated figures for the first time, reflecting its investment in the new subsidiary, Wanbury Skin Health Limited.

Why this matters

The company is aggressively pivoting toward the specialized healthcare segment. By incorporating Wanbury Skin Health Limited—in which it holds an 82% stake—Wanbury is diversifying away from its core business into the dermatology and baby care markets. While the establishment of this unit led to pre-operative expenses of Rs 3.36 crore during the quarter, it signals a long-term strategic shift toward high-margin consumer health categories.

Corporate Updates

Alongside the financial report, the company successfully executed an ESOP allotment, issuing 27,530 equity shares. This move increased the paid-up share capital by Rs 2.75 lakh, signaling management's confidence and commitment to employee stock ownership programs.

Governance and Audit

Investors can take comfort in the fact that the company’s statutory auditors have provided an unmodified opinion on the financial results, confirming the accuracy of the statements presented for the half-year period ending September 30, 2026.

What to track next

Watch for the commercial launch of products under the Wanbury Skin Health brand. Further expansion of this subsidiary's footprint could significantly impact consolidated profit margins in the coming quarters as pre-operative expenses normalize.